Q
Quant'AbondanceL'abondance, quantifiée.

Actualités

Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.

24,870 signal articles · 232 in last 24h · 118,518 total before filter · latest 1h ago
232last 24h
1529last 7d
251● bullish (7d)
159● bearish (7d)
205publishers
AllMacro296Earnings616M&A97Regulatory23Product14Analyst23
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Nutrien (NTR) Q2 Earnings Miss Estimates
Zacks13d agobearish
Nutrien (NTR) Q2 Earnings Miss Estimates

Nutrien (NTR) delivered earnings and revenue surprises of -3.33% and +1.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Klaviyo, Inc. (KVYO) Meets Q2 Earnings Estimates
Zacks13d agoneutral
Klaviyo, Inc. (KVYO) Meets Q2 Earnings Estimates

Klaviyo, Inc. (KVYO) delivered earnings and revenue surprises of 0.00% and +2.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance
Simply Wall St.13d agoneutral
Pfizer (PFE) Could Be 12% Undervalued Following Raised 2026 Revenue Guidance

Pfizer (PFE) is back in focus after its second quarter 2026 update, which paired a reported net loss and sizeable non cash impairments with higher full year revenue guidance and solid non COVID product performance. See our latest analysis for Pfizer. The latest results and raised revenue guidance have lifted sentiment toward Pfizer, with the stock showing a 1 month share price return of 8.81% and a 1 year total shareholder return of 15.42%, although longer term total shareholder returns...